U.S. trial begins on hyperopic hydrogel intracorneal lens

Trois Rivieres, Quebec-Participants in a U.S. phase I clinical trial evaluating a hydrogel intracorneal lens (PermaVision, Anamed Inc., Lake Forest, CA) for the treatment of hyperopia should benefit from the changes implemented as a resultof previous international experience, said Francis Roy, MD.